Drug and Narcotic Control
-
Subject Areas on Research
- 10 Years with ICH E10: Choice of Control Groups.
- A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.
- Assessing the present state and potential of Medicaid controlled substance lock-in programs.
- Association of State Opioid Duration Limits With Postoperative Opioid Prescribing.
- Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
- Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy.
- Drinking and Schooling
- Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
- Effects of the Office of National Drug Control Policy's Marijuana Initiative Campaign on high-sensation-seeking adolescents.
- Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.
- Impediments to clinical research in the United States.
- Improving the assessment of heart toxicity for all new drugs through translational regulatory science.
- Lock-In Programs and the Opioid Epidemic: A Call for Evidence.
- North Carolina Medicaid recipient management lock-in program: the pharmacist's perspective.
- People who use drugs, HIV, and human rights.
- Public health and international drug policy.
- Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes.
- Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
- Reducing Opioid Misuse: Evaluation of a Medicaid Controlled Substance Lock-In Program.
- Senator Royal Copeland. The medical and political career of a homeopathic physician.
- The economics of alcohol abuse and alcohol-control policies.
- The effect of Medicaid formularies on the availability of new drugs.
- The nonapproved use of medications.
- Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance "lock-in" program.
- Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
- Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.